Top Health Tech Companies With Best Stability & Growth (10,000+)

Strong Revenue Growth: Revenue is accelerating, with FY2025 up 19% year over year and Q4 2025 up 22%, followed by Q1 and Q2 2026 growth of 22% and 27%. Guidance for 2026 was raised to $94–$96 million, implying 22%–24% growth.

Strategic Partnerships: Collaborations with Mount Sinai (April 2026), Memorial Sloan Kettering (June 2026 precision medicine hub), and an expanded AstraZeneca alliance (August 2025) are highlighted as supporting platform adoption and data generation. Several large BioPharma contracts signed into late 2025/early 2026 further reinforce traction.

Customer Loyalty & Retention: Spending within the installed base is rising, with net dollar retention improving to 115% in 2025 and 117% in the first quarter of 2026. This coincides with rising analysis volumes across 2025–2026.

Profitability: Profitability is highlighted as first achieved in 2023 and sustained thereafter, with the company also describing itself as cash‑flow positive. These signals point to durable unit economics and financial health.

Strong Revenue Growth: Revenue is described as growing quickly over multiple years with momentum expected to continue, while efficiency benchmarks such as the Rule of 40 have been surpassed. Together, these indicators suggest efficient, scalable growth.

Strategic Partnerships: New integrations and channels—such as embedded real‑time booking on Yelp, Healthgrades, and Google’s Gemini, along with payer partnerships—are expanding distribution and reinforcing growth. These collaborations broaden patient access points and help providers secure bookings.

Investor Backing & Capital Strength: Capital momentum includes a $100M Series D in July 2024 at a higher valuation, signaling strong support for continued expansion. The raise is characterized as a notable step-up in a challenging health-tech funding climate.

Market Expansion: Geographic and payer reach are widening with nationwide availability and announced rollouts into Medicare Advantage by late 2024 and Medicaid in 2025. Broader plan connectivity and integrated primary care referral pathways indicate growth beyond the original commercial focus.

Strong Revenue Growth: Revenue is described as more than doubling over the prior 12 months alongside rising appointment volume and a rapidly expanding provider network. Milestones such as 1,000,000+ patients connected and millions of care hours delivered reinforce throughput growth.

Strong Revenue Growth: Revenue has risen across multiple periods, including fiscal 2025 up about 9% to roughly $321 billion and mid‑single‑digit year‑over‑year increases in fiscal 2026 quarters. Disclosures also note Q4 FY2025 revenue of $83.7 billion, up 5.9% year over year.

Profitability: Adjusted operating income and EPS expanded, with FY2025 adjusted EPS up 16% to $16.00 and Q2 FY2026 GAAP EPS rising to $8.40 alongside a raised full‑year adjusted EPS outlook to about $17.70–$17.90. Management also indicated double‑digit adjusted operating income growth expected for FY2026.

Resilient & Sustainable Growth: Momentum spans FY2023–FY2026 to date, with revenue progressing from about $262 billion (FY2023) to $294 billion (FY2024) to $321 billion (FY2025) and continued gains in 2026. Portfolio refocusing and acquisitions in specialty care (e.g., Retina Consultants of America, OneOncology) are described as engines supporting ongoing expansion and margin mix.

Profitability: Margins and earnings are expanding, with Q1 FY2026 adjusted EBITDA up, gross margin at 30.1%, and positive net income. FY2025 also delivered record free cash flow alongside margin expansion.

Customer Loyalty & Retention: Autoship represents a large, recurring base at 84.4% of Q1 FY2026 net sales, growing at a double‑digit pace. Rising net sales per active customer and cross‑category engagement point to stickier spend and retention.

Diversified Revenue Streams: Pet health services are scaling through SmartPak and the Modern Animal acquisition, complementing core e‑commerce with clinics and pharmacy. The Modern Animal deal is expected to add over $125M in annualized run‑rate revenue and expand clinics from 18 to 47, with additional openings planned in FY2026.

Strong Revenue Growth: Repeated Inc. 5000 recognition through 2025–2026 points to sustained multi‑year top‑line expansion. This ongoing external acknowledgement aligns with signals of continued growth momentum.

Market Expansion: The acquisition of Joshin in 2025 extends the platform into integrated neurodiversity and disability support, broadening the company’s reach beyond its historical software footprint. Partnerships and integrations with adjacent platforms further widen distribution and cross‑sell opportunities.

Innovation-Driven Growth: Multiple 2026 launches—Session Note AI, an AI Dashboard for ABA operations, and BillAI—illustrate a rapid product cadence aimed at deepening adoption and upsell. This pace of releases underscores continued investment in AI and workflow automation.

Strong Revenue Growth: Top line is described as expanding steadily in recent years, with continued growth expected. Separate reporting cites roughly $500 million in annual revenue and rapid momentum, even as exact figures vary.

Healthy Cash Flow: Cash generation has improved enough for a late‑2025 credit rating upgrade, with projections to produce over $100 million in free cash flow within the next 12–24 months. Leverage is expected to trend down alongside strong margins.

Customer Loyalty & Retention: Retention is characterized as consistently high with net expansion of spend, signaling durable relationships and effective cross‑sell within the installed base. A sizable customer count (over 4,000 organizations) supports stickiness across regions.

Innovation-Driven Growth: New AI-focused capabilities (e.g., AI Connectors built on Model Context Protocol) and a stated push to be an “AI platform for biotech R&D” signal ongoing product investment. Reported usage of Benchling AI across 500 biotech companies underscores adoption of these innovations.

Strategic Partnerships: The January 2026 collaboration with Lilly’s TuneLab is positioned to bring proprietary models to scientists across Benchling’s customer base. Acqui-hires of ReSync Bio and Sphinx Bio in 2025 were used to accelerate the AI roadmap.

Strong Revenue Growth: ARR was independently estimated around the low-$200 millions by mid-2024 with year-over-year increases, indicating continued top-line expansion. While the pace has moderated versus earlier years, the trajectory remains positive.

Investor Backing & Capital Strength: A $30M Series A led by Optum Ventures in March 2022, with participation from Cigna Ventures, provides runway and signals strong institutional confidence. This capital supports continued platform development and go‑to‑market efforts described since 2023.

Future-Ready Strategy: The October 10, 2023 divestiture of TPA operations to Vitori Health refocused the company on payer data exchange and an integration/iPaaS platform. This deliberate move is presented as enabling scale in the core software business.

Innovation-Driven Growth: Product evolution spans Flume OS (2021) and Flume Relay (March 2023), with active documentation and positioning around a healthcare payer integration layer. These launches and ongoing materials indicate a maturing, software‑centric platform into 2025–2026.

Investor Backing & Capital Strength: Fresh equity and debt in 2026—a $65M Series C in March and a $35M facility in July—provide resources to scale product and go-to-market, with management noting total 2026 funding surpassed $100M. These financings are corroborated by company disclosures and press coverage.

Market Expansion: Company communications describe expansion into hundreds of communities across multiple states, with named operators such as Navion and Novellus moving from pilots to broader rollouts. These signals point to cohort expansion rather than isolated deployments.

Strategic Partnerships: Live integrations with ALIS, ECP, and Yardi—plus PointClickCare and August Health slated in 2026—are positioned to extend reach across a large share of senior‑living workflows. The company frames these connections as enablers of nationwide deployment and day‑to‑day interoperability.

Resilient & Sustainable Growth: Growth is described as measured and predictable, with signals such as modest headcount expansion, sustained operating scale, and continued momentum rather than volatility.

Innovation-Driven Growth: Recent major releases across IRIS/IRIS for Health/Health Connect and new AI-focused offerings indicate ongoing R&D velocity that broadens capabilities and use cases.

Strong Market Position & Advantage: Repeated industry accolades for Shared Care Records/HIE and regional acute EHRs in 2026 point to durable competitive standing in core healthcare markets.

Market Expansion: Footprint growth from 120+ customers across 14 states in mid-2023 to "20+ states served" with 17,700+ completed requests and 8,800+ patients by 2025 indicates ongoing geographic and usage expansion.

Innovation-Driven Growth: A new partner portal effective May 1, 2026, together with a granted platform patent and AI-enabled request intake, points to continuous product development supporting scale.

Strategic Partnerships: Engagements with large health systems (e.g., an ongoing rollout across Emory Healthcare) and active onboarding of transportation partners suggest a strengthening ecosystem to drive growth.

Investor Backing & Capital Strength: The $30M Series B led by Andreessen Horowitz on February 26, 2025, with total funding cited at $50M, supplies meaningful capital to scale. Portfolio inclusion and public “doubling down” commentary from a16z reflect strong external validation.

Market Expansion: Company communications cite 81.8% more clinics and 163% more patients year over year, ~1.5M automated claims, and claims processed in all 50 states. Materials also note growth from an ABA beachhead into PT, ENT/Allergy, and plans for home health, long‑term care, and substance use disorders.

Innovation-Driven Growth: The platform is positioned as AI‑native RCM with reported ~93–95% first‑pass paid rates and one of the largest specialty claims datasets across ABA/SLP/OT/PT. Investor notes and case materials tie these capabilities to improved collections and denial reduction, supporting adoption.

Investor Backing & Capital Strength: Funding is described as a $15.5M Series A in October 2025 led by Costanoa Ventures with participation from Town Hall Ventures and Khosla Ventures, following an earlier 2024 seed. The round is explicitly framed to scale access, hiring, product, and market expansion.

Market Expansion: Go‑to‑market activity is described as expanding beyond New York into states like New Jersey and Ohio with active deployments and continued outreach into 2025–2026. Company materials and public profiles reference multi‑state operations and ongoing hiring to broaden footprint.

Strategic Partnerships: School‑district collaborations are highlighted (e.g., Millville Public Schools) alongside positioning as a school‑centered therapy platform aimed at K‑12 administrators and counselors. The model integrates school‑based referrals with insurer coverage, indicating partnership‑driven growth.

Investor Backing & Capital Strength: Large late-stage financing, including a $100M Series C in May 2026 that brought total funding to about $215M, signals ample runway and external confidence. Coverage of a valuation step-up around $1.75B and participation from prominent firms reinforces balance-sheet strength.

Strategic Partnerships: In‑network status with major insurers and expanding relationships with health plans, employers, and health systems are emphasized across recent materials. Access to 160M–200M+ covered lives and significant health‑system referrals indicate robust commercialization channels.

Strong Revenue Growth: Recognition on the 2026 Inc. 5000 and statements of year‑over‑year acceleration point to rapid top‑line expansion. Directional revenue signals align with sharp increases in patients served and provider capacity.

Investor Backing & Capital Strength: Recent financing includes a $50 million Series B in April 2025, described as oversubscribed and led by Key1 Capital. This injection is framed as fuel for hiring, product expansion, and go‑to‑market activity.

Strategic Partnerships: Channel integrations such as Homethrive and availability within the PrismHR ecosystem, along with selections by platforms like Vensure and a collaboration with TriNet, expand distribution reach. These moves are presented as widening access to employers and SMBs through established ecosystems.

Innovation-Driven Growth: Product velocity includes launches like Healthee Connect in 2025 and new AI capabilities such as AI-powered Claims Analytics and “Zoe for HR” in 2026. This cadence signals continued investment beyond core benefits Q&A toward analytics and broader platform functionality.

Investor Backing & Capital Strength: In March 2026, TPG’s The Rise Fund invested about $250 million in Findhelp to scale products and go-to-market. This capital is described as fuel to expand the national network and technology.

Market Expansion: State and HIE initiatives are broadening reach, including Tennessee’s Medicaid statewide launch and California’s Manifest MedEx data-sharing integration. These deployments extend coverage to large member populations and embed social–clinical data exchange.

Product Line Growth: The October 2025 acquisition of Uno Health added benefits eligibility and enrollment, positioning the platform as more end‑to‑end. Behavioral-health integrations such as the nationwide SimplePractice connection further widen use cases.

Investor Backing & Capital Strength: Advent International agreed on August 25, 2025 to acquire PatientPoint, with reporting at more than $1.4B, providing external validation and resources to accelerate expansion. This backing is positioned to support network growth and product innovation.

Product Line Growth: In March 2026 PatientPoint launched programmatic buying (Health Audiences) and a Consumer Health Network aimed at CPG/OTC brands, expanding how advertisers can buy and who the company serves. These additions broaden monetization beyond traditional life‑sciences sponsors.

Strong Market Position & Advantage: PatientPoint reports a nationwide footprint in 30,000+ physician offices and 125,000 providers, and in April 2026 received expanded Media Rating Council accreditation across its full digital screen network. This scale and third‑party validation bolster credibility for national buys.

Market Expansion: Public materials indicate the platform footprint has grown to 6,000+ research sites and 25+ sponsors, up from 5,500+ sites cited in late 2025, suggesting continued expansion into 2026. Geographic reach and site participation are portrayed as broadening across dozens of countries.

Strategic Partnerships: Collaborations with large biopharma (e.g., Sanofi, including a 2026 portfolio-level discussion) and integrations with ecosystem vendors like CRIO, RealTime-Devana, and eClinPro signal commercial traction and deeper ecosystem ties. These relationships are positioned to increase marketplace activity and data depth for sponsors and sites.

Innovation-Driven Growth: AI-powered pre-screening and workflow tooling launched in 2025 with ongoing case studies and integrations in 2026, aimed at accelerating enrollment and reducing site burden. The continued rollout of AI features and workflow enhancements suggests rising product maturity and adoption.

Product Line Growth: Launched and acquired products are expanding at a double‑digit pace (e.g., +18% operational in Q2 2026), led by assets such as Eliquis, Padcev, the Vyndaqel family, and Lorbrena. Excluding Comirnaty and Paxlovid, revenue grew mid‑single digits, signaling healthy momentum in the core portfolio.

Cost & Operational Efficiency: A multi‑year cost realignment targets about $5.7B in net savings by end‑2026, with a further $2.5B in productivity gains planned for 2027–2029. These actions have supported improved adjusted earnings even as headline revenue normalizes post‑COVID.

Innovation-Driven Growth: A robust late‑stage pipeline and oncology expansion following the Seagen acquisition underpin future growth, with numerous pivotal study starts in 2025–2026. Company commentary highlights oncology and obesity programs as key catalysts into the back half of the decade.